HeartWare International has appointed Stephen Oesterle to its board of directors. Oesterle’s career in cardiology and medical devices has spanned over 30 years, including senior leadership roles at Medtronic, and time spent as director of Invasive Cardiology Services at Massachusetts General Hospital, Boston, USA. Oesterle’s appointment brings the total HeartWare board to nine directors.
Oesterle currently is a Venture Partner with New Enterprise Associates (NEA), a global venture capital firm investing in technology and health care which he joined in 2015. He also acts as a strategic advisor to investment firms EQT and Temasek Holdings. Oesterle previously served as senior vice president for Medicine and Technology and as a member of the Executive Committee at Medtronic, which he joined in 2002.
During his tenure at Medtronic, Oesterle provided executive leadership for the company’s scientific research, the formation of technological strategies and the continued development of strong, cooperative relationships with medical communities, technical universities, financial institutions and emerging medical device companies around the world.
“Oesterle has extensive experience in the development of emerging medical therapies, with a broad strategic perspective in corporate management, as well as the clinical setting,” says Doug Godshall, president and chief executive officer at HeartWare. “Steve brings to HeartWare a tremendous clinical background in interventional cardiology, as well as a vision for the advancement of medical technology. His leadership, esteemed medical background and extensive relationships with researchers and innovators around the world will be of great value to HeartWare, as we seek to grow our business. We feel extraordinarily fortunate to have Steve joining our board.”
“The offer to join HeartWare’s Board of Directors was an opportunity that I eagerly accepted, as I am impressed by the strength of the company’s leadership and am enthusiastic about the potential to help HeartWare advance its prominence in the treatment of heart failure,” said Oesterle.
Earlier in his career, Oesterle served as associate professor of Medicine at the Harvard University Medical School and as director of Invasive Cardiology Services at Massachusetts General Hospital. He has also developed and directed interventional cardiology programs at Good Samaritan Hospital in Los Angeles, Georgetown University and Stanford University. Additionally, Oesterle has served as a consultant for medical device companies and has established scholarships to train cardiologists from developing countries. Oesterle graduated summa cum laude from Harvard and received his medical doctorate from Yale University. He was a post-doctoral fellow in cardiology at Stanford University, where he subsequently served on the faculty for more than a decade.
